<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0170302</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-41713</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Breast tumors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Breast tumors</subject><subj-group><subject>Breast cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular structures and organelles</subject><subj-group><subject>Cytoplasm</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Database and informatics methods</subject><subj-group><subject>Database searching</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Research design</subject><subj-group><subject>Cohort studies</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject><subj-group><subject>Endocrine therapy</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">P-mTOR Expression and Implication in Breast Carcinoma</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Ding</surname>
<given-names>Xian-Fei</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Li-Feng</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhou</surname>
<given-names>Xue-Liang</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Guo</surname>
<given-names>Li-Na</given-names>
</name>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Dou</surname>
<given-names>Meng-Meng</given-names>
</name>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chi</surname>
<given-names>Yan-Yan</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wu</surname>
<given-names>Shao-Xuan</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Ya-Na</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Shan</surname>
<given-names>Zheng-Zheng</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Yi-Jie</given-names>
</name>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Fan</surname>
<given-names>Qing-Xia</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Jie</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Tong-Wen</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of General ICU, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Gerontology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Department of Integrated Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Lee</surname>
<given-names>Jung Weon</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Seoul National University College of Pharmacy, REPUBLIC OF KOREA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> TWS LFL.</p></list-item> <list-item><p><bold>Data curation:</bold> XFD XLZ LNG.</p></list-item> <list-item><p><bold>Formal analysis:</bold> XFD MMD YYC SXW.</p></list-item> <list-item><p><bold>Funding acquisition:</bold> TWS.</p></list-item> <list-item><p><bold>Investigation:</bold> YNZ ZZS YJZ.</p></list-item> <list-item><p><bold>Methodology:</bold> LFL XLZ.</p></list-item> <list-item><p><bold>Resources:</bold> TWS.</p></list-item> <list-item><p><bold>Software:</bold> XLZ.</p></list-item> <list-item><p><bold>Supervision:</bold> TWS LNG QXF.</p></list-item> <list-item><p><bold>Validation:</bold> FW.</p></list-item> <list-item><p><bold>Visualization:</bold> TWS LFL.</p></list-item> <list-item><p><bold>Writing – original draft:</bold> XFD MMD.</p></list-item> <list-item><p><bold>Writing – review &amp; editing:</bold> TWS JZ.</p></list-item></list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">suntongwen@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>1</issue>
<elocation-id>e0170302</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Ding et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0170302"/>
<abstract>
<sec id="sec001">
<title>Objective</title>
<p>Phosphorylated mammalian target of rapamycin (p-mTOR) is a promising prognostic marker in many types of cancer. However, its survival benefit in patients with breast carcinoma remains unknown. The aim of the present study was to assess the relationship between p-mTOR expression and prognosis in breast carcinoma based on a systematic review and meta-analysis.</p>
</sec>
<sec id="sec002">
<title>Materials and Methods</title>
<p>Electronic databases (including Pubmed, Embase, ISI web of science, and Cochrane Library) were searched up to November 24, 2015. The outcome measures were hazard ratios (HRs) with 95% confidence interval (CI) for the association between the prognosis of breast carcinoma patients and p-mTOR expression. Primary end points were disease-free survival (DFS), overall survival (OS), and recurrence-free survival (RFS). Statistical analysis was performed with STATA 12.0.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Nine cohort studies including 3051 patients met full eligibility criteria. The pooled HRs (95% CI) for OS, DFS, and RFS were 0.84 (0.27–2.63), 0.71 (0.40–1.23), and 0.48 (0.20–1.18), respectively.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>Our findings suggested that p-mTOR overexpression was not significantly related to prognosis in breast carcinoma regarding OS and disease recurrence. Prospective studies are warranted to examine the association between p-mTOR expression and survival outcomes in breast carcinoma.</p>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>81370364</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Sun</surname>
<given-names>Tong-Wen</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>National Natural Science Foundation of China (CN)</institution>
</funding-source>
<award-id>71673254</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhao</surname>
<given-names>Jie</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>Science and Technology InnovationTeam in Universities of Henan province</institution>
</funding-source>
<award-id>16IRTSTHN021</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Sun</surname>
<given-names>Tong-Wen</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This study was supported by grants from the National Natural Science Foundation of China (nos. 81370364, 71673254), Science and Technology Innovation Team in Universities of Henan province (no. 16IRTSTHN021). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="2"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are included in the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Breast cancer is the leading cause of cancer-related death in women worldwide, with a mortality rate of 14% in female cancer patients [<xref ref-type="bibr" rid="pone.0170302.ref001">1</xref>]. A better understanding of the pathogenesis of breast carcinoma and advances in surgical, endocrinological, radiation, and chemical therapies dramatically improved the prognosis of patients with breast cancer; however, the 5 year survival rate remains low. New signaling pathways in breast cancer have been identified, and therapeutic modalities targeting these pathways may continue to improve the outcomes of cancer treatment [<xref ref-type="bibr" rid="pone.0170302.ref002">2</xref>].</p>
<p>Several new drugs have been developed to target specific signaling pathways in breast cancer, such as Herceptin, targeting the human epidermal growth factor receptor 2 (HER2) [<xref ref-type="bibr" rid="pone.0170302.ref003">3</xref>]. Despite promising results in clinical trials, drug resistance and genetic variations limit their further application [<xref ref-type="bibr" rid="pone.0170302.ref003">3</xref>]. Recent studies identified a potential signaling pathway named PI3K/AKT/mTOR, which plays an important role in survival, growth, proliferation, transformation, metabolism, and angiogenesis of tumor cells [<xref ref-type="bibr" rid="pone.0170302.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0170302.ref005">5</xref>]. PI3K and Akt can be phosphorylated in response to growth factors and nutrients, which activates mTOR, a highly conserved typical serine/threonine protein kinase [<xref ref-type="bibr" rid="pone.0170302.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0170302.ref007">7</xref>]. mTOR consists of two independent functional complexes, mTORC1 and mTORC2, which can be phosphorylated to p-mTOR. mTORCs directly phosphorylate and activate ribosome S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) [<xref ref-type="bibr" rid="pone.0170302.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0170302.ref009">9</xref>]. Their effect on activating 4EBP1 inhibits their capacity to repress the mRNA cap-binding protein eukaryotic initiation factor 4E (eIF4E) [<xref ref-type="bibr" rid="pone.0170302.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0170302.ref011">11</xref>]. Consequently, the main function of the mTORC-mediated signaling pathway is to regulate cell proliferation by activating ribosome biogenesis and protein synthesis [<xref ref-type="bibr" rid="pone.0170302.ref012">12</xref>, <xref ref-type="bibr" rid="pone.0170302.ref013">13</xref>]. Abnormal activation of the mTOR signaling pathway is associated with the development of many types of cancer [<xref ref-type="bibr" rid="pone.0170302.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0170302.ref015">15</xref>] and is present in 70% of breast carcinomas [<xref ref-type="bibr" rid="pone.0170302.ref016">16</xref>–<xref ref-type="bibr" rid="pone.0170302.ref018">18</xref>]. Therefore, the PI3K/AKT/mTOR pathway plays a key role in the development of breast carcinoma.</p>
<p>The effect of dysregulation of the mTOR signaling pathway on the survival of breast cancer patients has been reported extensively in recent years. However, the role of mTOR expression in the prognosis of breast cancer remains controversial. Based on the contradictory results from different studies, the aim of this meta-analysis was to assess the prognostic value of p-mTOR expression in patients with breast cancer.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec007">
<title>Search strategy</title>
<p>A literature search was performed using Pubmed, EMBASE, ISI Web of Science, and the Cochrane Library databases, covering all papers published up to November 2015. The search terms used in this meta-analysis met the following criteria: (1) Phosphorylated mammalian target of rapamycin or p-mTOR; (2) “Breast carcinoma” [Mesh] or “Breast Neoplasm” or “Breast Cancer” or “Breast carcinoma”; (3) prognosis or survive.</p>
</sec>
<sec id="sec008">
<title>Eligibility criteria</title>
<p>All languages were included; publications including only the abstract were excluded because of incomplete information. Titles and abstracts were examined first to eliminate unrelated studies, such as studies on cell lines or animals, reviews, and studies on other diseases. Then, all remaining articles were screened carefully for eligibility. Eligible articles were considered in this meta-analysis if they met the following criteria: (1) Definitive diagnosis of primary breast carcinoma; (2) Immunohistochemistry (IHC) or western blotting was used to measure the expression level of mTOR or p-mTOR; (3) Evaluation of studies addressing the correlation between mTOR or p-mTOR expression and breast carcinoma patients’ overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) among women; (4) Hazard ratio (HR) and 95% confidence interval (CI) were provided or could be calculated; (5) Included the latest and most complete study when involving more than one same cohort study of patients. Either abstracts or full texts were examined by two reviewers (Li-Feng Li and Xue-Liang Zhou) independently. Discrepancies were resolved by discussion with the third reviewer (Li-Na Guo).</p>
</sec>
<sec id="sec009">
<title>Data extraction</title>
<p>Eligible studies were evaluated independently by two researchers (Meng-Meng Dou and Xue-Liang Zhou), and the dispute was resolved by discussion with the third reviewer (Li-Feng Li). The extracted information was as follows: (1) first author, year of publication, nationality of patients, expression level of p-mTOR, number of p-mTOR-positive and -negative patients, histological type, clinical stage, and HR and 95% CI of OS, DFS, RFS. The quality of eligible studies was assessed using the Newcastle-Ottawa Scale (NOS).</p>
</sec>
<sec id="sec010">
<title>Statistical analysis</title>
<p>HR and 95% CI were used to assess the relationships between p-mTOR expression and DFS, OS, and RFS. Overexpression of p-mTOR was a risk factor for poor prognosis in breast cancer, especially when the HRs for DFS, OS, and RFS were &gt; 1 and the 95% CI did not overlap with 1. Some studies introduced the HR and 95% CI directly, whereas, in most studies, software (Engauge Digitizer Version 4. 1) could be used to analyze Kaplan-Meier survival curves and extract the HR and 95% CI values. This method was first reported by Parmar [<xref ref-type="bibr" rid="pone.0170302.ref019">19</xref>]. In addition, the Q test and <italic>I</italic><sup>2</sup> test were used to measure heterogeneity, which was not considered significant at <italic>P</italic> &gt; 0.05 or <italic>I</italic><sup><italic>2</italic></sup> &lt; 50%. The pooled HR of each study was calculated using the fixed-effects model (Mantel-Haenszel), or alternatively the random-effects model (DerSimonian and Laird). Provided heterogeneity existed, subgroup analysis was performed to explore potential sources of heterogeneity. One-way sensitivity analysis was used to assess the stability of the results. Begg’s funnel plot [<xref ref-type="bibr" rid="pone.0170302.ref020">20</xref>] and Egger’s linear regression [<xref ref-type="bibr" rid="pone.0170302.ref021">21</xref>] were used to assess potential publication bias. All analyses were performed using Stata 12.0 statistical software (Stata Corp LP, College Station, TX, USA). Differences with <italic>P</italic> &lt; 0.05 (two-sided) were considered statistically significant.</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<sec id="sec012">
<title>Study characteristics of the included literature</title>
<p>Nine articles involving 3051 patients [<xref ref-type="bibr" rid="pone.0170302.ref022">22</xref>–<xref ref-type="bibr" rid="pone.0170302.ref030">30</xref>] were included in the analysis after assessment of duplication (<xref ref-type="fig" rid="pone.0170302.g001">Fig 1</xref>). Three and five studies were analyzed by multivariate and univariate methods, respectively, and one study was analyzed using both methods. In the summary analysis, multivariate data were extracted when the results involved multivariate and univariate analyses, taking confounding factors into account. Eight studies provided integrated original information of the relationship between p-mTOR expression and clinical pathological parameters in breast carcinoma directly [<xref ref-type="bibr" rid="pone.0170302.ref022">22</xref>–<xref ref-type="bibr" rid="pone.0170302.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0170302.ref027">27</xref>–<xref ref-type="bibr" rid="pone.0170302.ref029">29</xref>]. One article assessed the prognostic value of p-mTOR (DFS) in breast carcinoma by the Kaplan-Meier method [<xref ref-type="bibr" rid="pone.0170302.ref026">26</xref>]. In all studies, IHC and paraffin-embedded specimens were used. The main characteristics of the nine cohort studies involved in our meta-analysis are shown in <xref ref-type="table" rid="pone.0170302.t001">Table 1</xref>.</p>
<fig id="pone.0170302.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow diagram of study selection.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0170302.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of studies on p-mTOR expression.</title></caption>
<alternatives>
<graphic id="pone.0170302.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">First author</th>
<th align="center">Country</th>
<th align="center">Year</th>
<th align="center">No.of patients(mTOR high/low)</th>
<th align="center">Age(years)</th>
<th align="center">Pathological types(IDC/ILC/Other)</th>
<th align="center">Stage(I/II/III/IV)</th>
<th align="center">The median follow-up period(months)</th>
<th align="center">HR(95% CI)of DFS</th>
<th align="center">HR(95% CI)of OS</th>
<th align="center">HR(95% CI)of RFS</th>
<th align="center">IHC positive Cutoff value</th>
<th align="center">Location of cell</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Emiel A.M. J[<xref ref-type="bibr" rid="pone.0170302.ref019">19</xref>]</td>
<td align="center">Netherlands</td>
<td align="center">2007</td>
<td align="center">125(81/44)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">134</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">0.6 (0.2–1.6)</td>
<td align="center">≥10%</td>
<td align="center">Cytoplasm</td>
</tr>
<tr>
<td align="center">MA[<xref ref-type="bibr" rid="pone.0170302.ref020">20</xref>]</td>
<td align="center">China</td>
<td align="center">2015</td>
<td align="center">285(206/79)</td>
<td align="center">28–73</td>
<td align="center">244/11/30</td>
<td align="center">I, 65; II, 220</td>
<td align="center">71.8</td>
<td align="center">0.787(0.571–1.085)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">&gt;80%</td>
<td align="center">Cytoplasm</td>
</tr>
<tr>
<td align="center">Francisco B[<xref ref-type="bibr" rid="pone.0170302.ref021">21</xref>]</td>
<td align="center">Canada</td>
<td align="center">2015</td>
<td align="center">331(145/186)</td>
<td align="left">≤ 50,130; &gt;50,201</td>
<td align="center">228/18/85</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">0.40 (0.22–0.72)</td>
<td align="center">0.26(0.11–0.61)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">Cytoplasm</td>
</tr>
<tr>
<td align="center">Georgios L[<xref ref-type="bibr" rid="pone.0170302.ref022">22</xref>]</td>
<td align="center">Greece</td>
<td align="center">2014</td>
<td align="center">997(738/259)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">105</td>
<td align="center">0.27(0.13–0.59)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="center">Shikha B[<xref ref-type="bibr" rid="pone.0170302.ref023">23</xref>]</td>
<td align="center">US</td>
<td align="center">2006</td>
<td align="center">138(33/105)</td>
<td align="center">NA</td>
<td align="center">138/0/0</td>
<td align="center">NA</td>
<td align="center">60</td>
<td align="center">3.1 (1.27–7.56)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">Cytoplasm; Nuclear</td>
</tr>
<tr>
<td align="center">Panagiotis B[<xref ref-type="bibr" rid="pone.0170302.ref024">24</xref>]</td>
<td align="center">Greece</td>
<td align="center">2010</td>
<td align="center">192(131/61)</td>
<td align="center">56 (25–87)</td>
<td align="center">155/30/7</td>
<td align="left">48/132/12/0</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">2.35(0.96–5.77)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">Cytoplasm</td>
</tr>
<tr>
<td align="center">Shir-Hwa U[<xref ref-type="bibr" rid="pone.0170302.ref025">25</xref>]</td>
<td align="center">China</td>
<td align="center">2012</td>
<td align="center">172(124/48)</td>
<td align="left">≤ 45, 65; &gt;45,107</td>
<td align="center">0/157/15</td>
<td align="center">I-II, 125</td>
<td align="center">68.84</td>
<td align="center">NA</td>
<td align="center">0.97 (0.51–1.84)</td>
<td align="center">0.75 (0.43–1.3)</td>
<td align="center">1–10%MSP,5–50%WP</td>
<td align="center">Cytoplasm; Nuclear</td>
</tr>
<tr>
<td align="center">Jungsuk A[<xref ref-type="bibr" rid="pone.0170302.ref026">26</xref>]</td>
<td align="center">Korea</td>
<td align="center">2010</td>
<td align="center">530(207/136)</td>
<td align="center">46.0 (26–85)</td>
<td align="center">497/33/0</td>
<td align="center">158/264/93/15</td>
<td align="center">58.50</td>
<td align="center">0.794(0.515–1.225)</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">≥10%SP,&gt;50%WP</td>
<td align="center">Cytoplasm; Nuclear</td>
</tr>
<tr>
<td align="center">Karin B[<xref ref-type="bibr" rid="pone.0170302.ref027">27</xref>]</td>
<td align="center">Netherlands</td>
<td align="center">2014</td>
<td align="center">421(89/332)</td>
<td align="left">&lt;65,210; ≥65,228</td>
<td align="center">NA</td>
<td align="center">I-II, 388; III-IV, 50</td>
<td align="center">93.60</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">0.11 (0.02–0.55)</td>
<td align="center">NA</td>
<td align="center">Cytoplasm</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Abbreviations: NA, information not available; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; SP, strong positive; MSP, moderately strong positive; WP, weak positive.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec013">
<title>Quality assessment</title>
<p>Quality assessment for eligible studies was performed using the NOS, which is recommended by the Cochrane Non-Randomized Studies Methods Working Group [<xref ref-type="bibr" rid="pone.0170302.ref031">31</xref>]. In this scale, studies are assessed based on three criteria, selection, comparability, and outcome. The quality of each study is graded with a maximum of eight stars. Grading was as follows: &lt; five stars represented low quality and &gt; six stars represented high quality. Quality assessment was performed by two investigators (Yan-Yan Chi and Shao-Xuan Wu), and any differences were resolved by Li-Na Guo. The NOS for quality assessment is shown in <xref ref-type="table" rid="pone.0170302.t002">Table 2</xref>. All studies had adequate selection of patients, with true representation of the average breast carcinoma patients in the community. Long-term follow-up was sufficient to determine outcomes. For the other parts, scores were similar to each other.</p>
<table-wrap id="pone.0170302.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.t002</object-id>
<label>Table 2</label> <caption><title>The Newcastle-Ottawa Scale (NOS) for assessing the quality of cohort studies.</title></caption>
<alternatives>
<graphic id="pone.0170302.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">RC studies</th>
<th align="center" colspan="3">Selection</th>
<th align="center" colspan="2">Comparability</th>
<th align="center" colspan="3">Assessment of outcome</th>
<th align="center">Total quality score</th>
</tr>
<tr>
<th align="center">First author</th>
<th align="left">Representativeness of mTOR positive arm</th>
<th align="left">Selection of the comparative mTOR negative arm (s)</th>
<th align="left">Ascertainment of mTOR positive regimen</th>
<th align="left">Demonstration that outcome of interest was not present at start of study</th>
<th align="center">Comparability between patients in different mTOR positive and negative arms-main factor: IHC positive Cut off value</th>
<th align="left">Assessment of outcome with independency</th>
<th align="left">Adequacy of Follow up length (to assess outcome)</th>
<th align="left">Lost to follow up acceptable (less than 10% and reported)</th>
<th align="center">HR(95% CI)of OS</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Emiel A.M. J[<xref ref-type="bibr" rid="pone.0170302.ref019">19</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">6</td>
</tr>
<tr>
<td align="center">MA[<xref ref-type="bibr" rid="pone.0170302.ref020">20</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">7</td>
</tr>
<tr>
<td align="center">Francisco B[<xref ref-type="bibr" rid="pone.0170302.ref021">21</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center"/>
<td align="center"/>
<td align="center">5</td>
</tr>
<tr>
<td align="center">Georgios L[<xref ref-type="bibr" rid="pone.0170302.ref022">22</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">5</td>
</tr>
<tr>
<td align="center">Shikha B[<xref ref-type="bibr" rid="pone.0170302.ref023">23</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">6</td>
</tr>
<tr>
<td align="center">Panagiotis B[<xref ref-type="bibr" rid="pone.0170302.ref024">24</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center"/>
<td align="center"/>
<td align="center">5</td>
</tr>
<tr>
<td align="center">Shir-Hwa U[<xref ref-type="bibr" rid="pone.0170302.ref025">25</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">7</td>
</tr>
<tr>
<td align="center">Jungsuk A[<xref ref-type="bibr" rid="pone.0170302.ref026">26</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">7</td>
</tr>
<tr>
<td align="center">Karin B[<xref ref-type="bibr" rid="pone.0170302.ref027">27</xref>]</td>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center"/>
<td align="center">*</td>
<td align="center">*</td>
<td align="center"/>
<td align="center">5</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Abbreviations: RC, retrospective cohort study.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Relationship between p-mTOR expression and DFS, OS, and RFS in breast carcinoma</title>
<p>Five [<xref ref-type="bibr" rid="pone.0170302.ref022">22</xref>–<xref ref-type="bibr" rid="pone.0170302.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0170302.ref029">29</xref>], three [<xref ref-type="bibr" rid="pone.0170302.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0170302.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0170302.ref028">28</xref>], and three [<xref ref-type="bibr" rid="pone.0170302.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0170302.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0170302.ref030">30</xref>]studies reported the HR and 95% CI for DFS, OS, and RFS, respectively. The results of the meta-analysis are shown in Figs <xref ref-type="fig" rid="pone.0170302.g002">2</xref>–<xref ref-type="fig" rid="pone.0170302.g004">4</xref>. The pooled HRs for DFS, OS, and RFS were 0.71 (95% CI: 0.40–1.23), 0.84 (95% CI: 0.27–2.63), and 0.48 (95% CI: 0.20–1.18), respectively, which indicated no statistically significant relationship between p-mTOR expression and DFS, OS, and RFS in breast carcinoma patients. Therefore, we concluded that p-mTOR overexpression was not significantly related to the survival of breast carcinoma patients regarding disease recurrence and OS. A random-effects model was used to perform the meta-analysis because of mild or significant heterogeneity (respectively, <italic>P</italic> &lt; 0.001, <italic>I</italic><sup>2</sup> = 81.0%; <italic>P</italic> = 0.002, <italic>I</italic><sup>2</sup> = 83.9%; and <italic>P</italic> = 0.098, <italic>I</italic><sup>2</sup> = 56.9%) among the studies.</p>
<fig id="pone.0170302.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Meta-analysis of the overall pooled hazard ratios (HRs) of studies for the survival outcomes of breast cancer.</title>
<p>Forest plot showing no statistical significance of the association between p-mTOR expression and disease-free survival of breast cancer patients from the random-effects model.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0170302.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Meta-analysis of the overall pooled HR of studies for the survival outcomes of breast cancer.</title>
<p>Forest plot showing no statistical significance of the association between p-mTOR expression and overall survival of breast cancer patients from the random-effects model.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g003" xlink:type="simple"/>
</fig>
<fig id="pone.0170302.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Meta-analysis of the overall pooled HR of studies for recurrence of breast cancer.</title>
<p>Forest plot showing no statistical significance of association between p-mTOR expression and recurrence-free survival of breast cancer patients from the random-effects model.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Subgroup analysis</title>
<p>Studies were stratified to evaluate the HR of DFS according to p-mTOR expression by region (Western and Eastern) and the number of patients included in the study (&gt; 300 patients and &lt; 300 patients). The results of this subgroup analysis are shown in Figs <xref ref-type="fig" rid="pone.0170302.g005">5</xref> and <xref ref-type="fig" rid="pone.0170302.g006">6</xref>. For the study region, studies from Eastern and Western countries showed no statistically significant differences (HR = 0.79, 95% CI = 0.61–1.02, <italic>I</italic><sup><italic>2</italic></sup> = 0.0%, <italic>P</italic> = 0.974; HR = 0.67, 95% CI = 0.16–2.51,<italic>I</italic><sup><italic>2</italic></sup> = 89.4%, <italic>P</italic> &lt; 0.001, respectively). In the stratification by patients, the &gt; 300 group showed statistical significance (HR = 0.47, 95% CI = 0.25–0.87, <italic>I</italic><sup><italic>2</italic></sup> = 72.4%, <italic>P</italic> = 0.027), whereas studies from the &lt; 300 group had no statistical significance (HR = 1.48, 95% CI = 0.38–5.57,<italic>I</italic><sup><italic>2</italic></sup> = 81.0%, <italic>P</italic> &lt; 0.001).</p>
<fig id="pone.0170302.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Subgroup analysis indicates that there is no statistical significance according to study region (Western and Eastern).</title>
<p>Forest plot showing the association between p-mTOR expression and disease-free survival of breast cancer patients from the random-effects model.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g005" xlink:type="simple"/>
</fig>
<fig id="pone.0170302.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Subgroup analysis indicates statistical significance in the subgroup of &gt; 300 patients.</title>
<p>Forest plot showing the association between p-mTOR expression and disease-free survival of breast cancer patients from the random-effects model.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g006" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec016">
<title>Sensitivity analysis</title>
<p>Sensitivity analysis was performed to assess the influence of any one study on the pooled HRs and CIs by omitting one individual study at a time. Our findings showed that the results were robust and reliable (<xref ref-type="fig" rid="pone.0170302.g007">Fig 7</xref>) (data not shown).</p>
<fig id="pone.0170302.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Sensitivity analysis showed that the studies were robust and reliable regarding p-mTOR expression and disease-free survival of breast cancer.</title>
<p>The analysis was performed by excluding one study at a time and calculating the pooled estimate for the remaining studies.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g007" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec017">
<title>Publication bias</title>
<p>Begg’s funnel plots and Egger’s linear regression tests were performed to evaluate publication bias (<xref ref-type="fig" rid="pone.0170302.g008">Fig 8</xref>). No significant publication bias was found for the association between p-mTOR expression and DFS (Begg’s test, <italic>P</italic> = 0.806; Egger’s test, <italic>P</italic> = 0.954).</p>
<fig id="pone.0170302.g008" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0170302.g008</object-id>
<label>Fig 8</label>
<caption>
<title>Begg’s funnel plot indicates no significant publication bias regarding p-mTOR expression and disease-free survival outcomes in breast cancer.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.g008" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec018" sec-type="conclusions">
<title>Discussion</title>
<p>The present meta-analysis, which included nine articles and 3051 participants, assessed the significance of p-mTOR expression in breast cancer. The results showed that p-mTOR overexpression was not significantly associated with the survival of breast carcinoma patients regarding disease recurrence and OS. However, the heterogeneity of the Eastern subgroup was significantly reduced after stratification by region into Western and Eastern countries. Moreover, significant associations between p-mTOR expression and prognosis were identified in subgroups of &gt; 300 patients.</p>
<p>mTOR is a 290 kDa molecule that functions as a serine-threonine kinase to regulate cell growth and metabolism through the mTOR signaling pathway [<xref ref-type="bibr" rid="pone.0170302.ref032">32</xref>]. Aberrant activation of the PI3K/Akt/mTOR signaling pathway is involved in oncogenesis and disease progression in breast carcinoma [<xref ref-type="bibr" rid="pone.0170302.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0170302.ref033">33</xref>, <xref ref-type="bibr" rid="pone.0170302.ref034">34</xref>]. Uenget al.[<xref ref-type="bibr" rid="pone.0170302.ref028">28</xref>] reported that p-mTOR expression is an adverse prognostic indicator in early-stage (stage I and II) triple negative breast cancer, whereas it is not statistically significant in patients with stage III and IV. Bose et al.[<xref ref-type="bibr" rid="pone.0170302.ref026">26</xref>] showed that p-mTOR overexpression is associated with a 3-fold greater risk of disease recurrence in breast cancer. Zhou et al.[<xref ref-type="bibr" rid="pone.0170302.ref002">2</xref>] showed that p-mTOR is positively associated with HER-2 overexpression and correlated with poor DFS in patients with breast cancer. Bakarakos et al.[<xref ref-type="bibr" rid="pone.0170302.ref027">27</xref>] demonstrated that p-mTOR is positively associated with lymph node status and has a negative effect on survival outcome in invasive breast cancer. However, Annovazzi et al.[<xref ref-type="bibr" rid="pone.0170302.ref035">35</xref>] found no statistically significant association between p-mTOR expression and survival outcomes. A triple negative breast cancer study [<xref ref-type="bibr" rid="pone.0170302.ref028">28</xref>] showed that the majority of tumors (72.1%) are p-mTOR positive, whereas expression of p-mTOR is notcorrelated with tumor grade, lymph node status, and stage. Activation of the mTOR signaling pathway is associated with a more aggressive phenotype in both triple negative breast cancer and non-triple negative breast cancer. In short, the mechanism underlying the effect of the p-mTOR signaling pathway on breast cancer is complex, and numerous studies are necessary to elucidate it.</p>
<p>The prognostic significance of p-mTOR expression has been explored extensively in many types of cancer; however, the results remain controversial. Cai et al.[<xref ref-type="bibr" rid="pone.0170302.ref036">36</xref>]reported that overexpression of p-mTOR is associated with poor prognosis in early-stage breast carcinoma patients, with 5year survival rates of 32.7% and 56.4% for p-mTOR-positive and -negative patients, respectively. Survival analysis in a study by Leal[<xref ref-type="bibr" rid="pone.0170302.ref037">37</xref>] indicated that high p-mTOR expression is associated with poor prognosis in patients with advanced gallbladder adenocarcinoma. However, Valsamo et al.[<xref ref-type="bibr" rid="pone.0170302.ref038">38</xref>]showed that early-stage lung adenocarcinoma patients with high p-mTOR expression have a longer median OS than those with low expression. A meta-analysis performed by Lei Li et al.[<xref ref-type="bibr" rid="pone.0170302.ref039">39</xref>] reported no statistically significant association between p-mTOR expression and the prognosis of non-small cell lung cancer patients. Therefore, the clinical significance of p-mTOR expression in different cancers remains unclear.</p>
<p>mTOR inhibitors such as everolimus, which are targeted drugs in breast carcinoma, have been extensively tested in clinical trials for breast carcinoma. Everolimus in oral dosage form has been approved by the US Food and Drug Administration for the treatment of estrogen receptor-positive postmenopausal breast carcinoma patients [<xref ref-type="bibr" rid="pone.0170302.ref040">40</xref>]. In addition, a phase III randomized clinical trial conducted by Baselga et al.[<xref ref-type="bibr" rid="pone.0170302.ref041">41</xref>] showed that everolimus combined with exemestane improved progression-free survival (PFS) in patients with hormone receptor-positive advanced breast carcinoma that was previously treated, compared with the exemestane plus placebo arm. Similarly, a phase III, double-blind, randomized, international study (the BOLERO-2) [<xref ref-type="bibr" rid="pone.0170302.ref042">42</xref>] showed that the PFS of the everolimus plus exemestane arm was 8.5 months compared with 4.2 months in the placebo plus exemestane arm. A different study, BOLERO-3 [<xref ref-type="bibr" rid="pone.0170302.ref043">43</xref>], reported that the addition of everolimus to trastuzumab plus vinorelbine significantly prolonged PFS in patients with trastuzumab-resistant and taxane-pretreated, HER-2-positive, advanced breast carcinoma. These studies are inconsistent with the results of our meta-analysis, which could be attributed to the limited number of original articles included in the present meta-analysis.</p>
<p>The present meta-analysis has four advantages. First, it is the first meta-analysis assessing the clinical and prognostic role of p-mTOR expression in breast carcinoma. Second, the sensitivity analysis showed no significant difference when any one article of five was removed, which indicated that the association between clinicopathological parameters and DFS was relatively stable and credible. Third, no publication bias was detected. Finally, the original cases of the included studies had a good representation in breast carcinoma through strict inclusion and screening criteria, indicating that the results of the meta-analysis were reliable.</p>
<p>The present meta-analysis had several limitations. First, despite the fact that all studies met the inclusion criteria, the IHC cut-off points for the detection of positive or negative p-mTOR expression were not consistent. Second, some HR and 95% CI values obtained from Kaplan-Meier (K-M) curves were not precise. Finally, as the included studies did not provide complete information about patients, subgroup analysis according to pathological type and stage was not performed; the analysis was only stratified to evaluate the HR of DFS according to p-mTOR expression by region (Western and Eastern) and number of patients included the studies (&gt; 300 patients and &lt; 300 patients).</p>
<p>In conclusion, compared with low p-mTOR expression, p-mTOR overexpression was not significantly related to the prognosis of breast carcinoma patients regarding OS and disease recurrence. An updated meta-analysis including a larger number of original studies may provide further insight. Future studies should meet the following criteria: first, baseline characteristics should be balanced among groups, including country, race, pathological types, stage, tumor size, lymph node status, number of patients, median age, and follow-up period, with HR and 95% CI data for progression or death, adjuvant therapy, previous sensitivity to endocrine therapy, estrogen-receptor and ECOG performance status, and metastatic site. Second, adverse events and their grade, including anemia, hyperglycemia, fatigue, and pneumonitis, should be reported. Third, a sample number &gt; 500 patients is needed.</p>
</sec>
<sec id="sec019">
<title>Supporting Information</title>
<supplementary-material id="pone.0170302.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.s001" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>PRISMA 2009 flow diagram.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0170302.s002" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0170302.s002" xlink:type="simple">
<label>S2 File</label>
<caption>
<title>PRISMA 2009 checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>4EBP1</term>
<def><p>transcription initiation factor 4E-binding protein 1</p></def>
</def-item>
<def-item><term>CI</term>
<def><p>confidence interval</p></def>
</def-item>
<def-item><term>DFS</term>
<def><p>disease-free survival</p></def>
</def-item>
<def-item><term>eIF4E</term>
<def><p>transcription initiation factor 4E</p></def>
</def-item>
<def-item><term>HR</term>
<def><p>hazard ratio</p></def>
</def-item>
<def-item><term>IHC</term>
<def><p>immunohistochemistry</p></def>
</def-item>
<def-item><term>OS</term>
<def><p>overall survival</p></def>
</def-item>
<def-item><term>p-mTOR</term>
<def><p>phosphorylated mammalian target of rapamycin</p></def>
</def-item>
<def-item><term>RFS</term>
<def><p>recurrence-free survival</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pone.0170302.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bray</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Center</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Ferlay</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ward</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Forman</surname> <given-names>D</given-names></name>. <article-title>Global cancer statistics</article-title>. <source>CA: a cancer journal for clinicians</source>. <year>2011</year>;<volume>61</volume>(<issue>2</issue>):<fpage>69</fpage>–<lpage>90</lpage>. Epub 2011/02/08.</mixed-citation></ref>
<ref id="pone.0170302.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Stone Hawthorne</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Klos</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Lan</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers</article-title>. <source>Clin Cancer Res</source>. <year>2004</year>;<volume>10</volume>(<issue>20</issue>):<fpage>6779</fpage>–<lpage>88</lpage>. Epub 2004/10/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-04-0112" xlink:type="simple">10.1158/1078-0432.CCR-04-0112</ext-link></comment> <object-id pub-id-type="pmid">15501954</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vogel</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Cobleigh</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Tripathy</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gutheil</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>LN</given-names></name>, <name name-style="western"><surname>Fehrenbacher</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2002</year>;<volume>20</volume>(<issue>3</issue>):<fpage>719</fpage>–<lpage>26</lpage>. Epub 2002/02/01.</mixed-citation></ref>
<ref id="pone.0170302.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dobashi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Watanabe</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Miwa</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Koyama</surname> <given-names>S</given-names></name>. <article-title>Mammalian target of rapamycin: a central node of complex signaling cascades</article-title>. <source>International journal of clinical and experimental pathology</source>. <year>2011</year>;<volume>4</volume>(<issue>5</issue>):<fpage>476</fpage>–<lpage>95</lpage>. Epub 2011/07/09. <object-id pub-id-type="pmid">21738819</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wullschleger</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Loewith</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hall</surname> <given-names>MN</given-names></name>. <article-title>TOR signaling in growth and metabolism</article-title>. <source>Cell</source>. <year>2006</year>;<volume>124</volume>(<issue>3</issue>):<fpage>471</fpage>–<lpage>84</lpage>. Epub 2006/02/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2006.01.016" xlink:type="simple">10.1016/j.cell.2006.01.016</ext-link></comment> <object-id pub-id-type="pmid">16469695</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hay</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Sonenberg</surname> <given-names>N</given-names></name>. <article-title>Upstream and downstream of mTOR</article-title>. <source>Genes &amp; development</source>. <year>2004</year>;<volume>18</volume>(<issue>16</issue>):<fpage>1926</fpage>–<lpage>45</lpage>. Epub 2004/08/18.</mixed-citation></ref>
<ref id="pone.0170302.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shaw</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Cantley</surname> <given-names>LC</given-names></name>. <article-title>Ras, PI(3)K and mTOR signalling controls tumour cell growth</article-title>. <source>Nature</source>. <year>2006</year>;<volume>441</volume>(<issue>7092</issue>):<fpage>424</fpage>–<lpage>30</lpage>. Epub 2006/05/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature04869" xlink:type="simple">10.1038/nature04869</ext-link></comment> <object-id pub-id-type="pmid">16724053</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Holz</surname> <given-names>MK</given-names></name>. <article-title>The role of S6K1 in ER-positive breast cancer</article-title>. <source>Cell cycle (Georgetown, Tex)</source>. <year>2012</year>;<volume>11</volume>(<issue>17</issue>):<fpage>3159</fpage>–<lpage>65</lpage>. Epub 2012/08/17.</mixed-citation></ref>
<ref id="pone.0170302.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kenerson</surname> <given-names>HL</given-names></name>, <name name-style="western"><surname>Aicher</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>True</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>Yeung</surname> <given-names>RS</given-names></name>. <article-title>Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors</article-title>. <source>Cancer research</source>. <year>2002</year>;<volume>62</volume>(<issue>20</issue>):<fpage>5645</fpage>–<lpage>50</lpage>. Epub 2002/10/18. <object-id pub-id-type="pmid">12384518</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asnaghi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Bruno</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Priulla</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nicolin</surname> <given-names>A</given-names></name>. <article-title>mTOR: a protein kinase switching between life and death</article-title>. <source>Pharmacological research</source>. <year>2004</year>;<volume>50</volume>(<issue>6</issue>):<fpage>545</fpage>–<lpage>9</lpage>. Epub 2004/10/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.phrs.2004.03.007" xlink:type="simple">10.1016/j.phrs.2004.03.007</ext-link></comment> <object-id pub-id-type="pmid">15501691</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mamane</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Petroulakis</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>LeBacquer</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Sonenberg</surname> <given-names>N</given-names></name>. <article-title>mTOR, translation initiation and cancer</article-title>. <source>Oncogene</source>. <year>2006</year>;<volume>25</volume>(<issue>48</issue>):<fpage>6416</fpage>–<lpage>22</lpage>. Epub 2006/10/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.onc.1209888" xlink:type="simple">10.1038/sj.onc.1209888</ext-link></comment> <object-id pub-id-type="pmid">17041626</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chung</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Grammer</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Lemon</surname> <given-names>KP</given-names></name>, <name name-style="western"><surname>Kazlauskas</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Blenis</surname> <given-names>J</given-names></name>. <article-title>PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase</article-title>. <source>Nature</source>. <year>1994</year>;<volume>370</volume>(<issue>6484</issue>):<fpage>71</fpage>–<lpage>5</lpage>. Epub 1994/07/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/370071a0" xlink:type="simple">10.1038/370071a0</ext-link></comment> <object-id pub-id-type="pmid">8015612</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hara</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yonezawa</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kozlowski</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Sugimoto</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Andrabi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Weng</surname> <given-names>QP</given-names></name>, <etal>et al</etal>. <article-title>Regulation of eIF-4E BP1 phosphorylation by mTOR</article-title>. <source>The Journal of biological chemistry</source>. <year>1997</year>;<volume>272</volume>(<issue>42</issue>):<fpage>26457</fpage>–<lpage>63</lpage>. Epub 1997/10/23. <object-id pub-id-type="pmid">9334222</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yu</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Pan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>(<issue>5</issue>):<fpage>1821</fpage>–<lpage>9</lpage>. Epub 2009/02/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-08-2138" xlink:type="simple">10.1158/1078-0432.CCR-08-2138</ext-link></comment> <object-id pub-id-type="pmid">19223493</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rolfo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Giovannetti</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Bivona</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Raez</surname> <given-names>LE</given-names></name>, <name name-style="western"><surname>Bronte</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors</article-title>. <source>Cancer treatment reviews</source>. <year>2014</year>;<volume>40</volume>(<issue>8</issue>):<fpage>990</fpage>–<lpage>1004</lpage>. Epub 2014/06/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ctrv.2014.05.009" xlink:type="simple">10.1016/j.ctrv.2014.05.009</ext-link></comment> <object-id pub-id-type="pmid">24953979</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lauring</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>BH</given-names></name>, <name name-style="western"><surname>Wolff</surname> <given-names>AC</given-names></name>. <article-title>The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer</article-title>. <source>Journal of the National Comprehensive Cancer Network: JNCCN</source>. <year>2013</year>;<volume>11</volume>(<issue>6</issue>):<fpage>670</fpage>–<lpage>8</lpage>. Epub 2013/06/08. <object-id pub-id-type="pmid">23744866</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stephens</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Tarpey</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Davies</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Van Loo</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Greenman</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wedge</surname> <given-names>DC</given-names></name>, <etal>et al</etal>. <article-title>The landscape of cancer genes and mutational processes in breast cancer</article-title>. <source>Nature</source>. <year>2012</year>;<volume>486</volume>(<issue>7403</issue>):<fpage>400</fpage>–<lpage>4</lpage>. Epub 2012/06/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature11017" xlink:type="simple">10.1038/nature11017</ext-link></comment> <object-id pub-id-type="pmid">22722201</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Network</surname> <given-names>CGA</given-names></name>. <article-title>Comprehensive molecular portraits of human breast tumours</article-title>. <source>Nature</source>. <year>2012</year>;<volume>490</volume>(<issue>7418</issue>):<fpage>61</fpage>–<lpage>70</lpage>. Epub 2012/09/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature11412" xlink:type="simple">10.1038/nature11412</ext-link></comment> <object-id pub-id-type="pmid">23000897</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parmar</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Torri</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>L</given-names></name>. <article-title>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</article-title>. <source>Statistics in medicine</source>. <year>1998</year>;<volume>17</volume>(<issue>24</issue>):<fpage>2815</fpage>–<lpage>34</lpage>. Epub 1999/01/28. <object-id pub-id-type="pmid">9921604</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>101</lpage>. Epub 1994/12/01. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ (Clinical research ed)</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>34</lpage>. Epub 1997/10/06.</mixed-citation></ref>
<ref id="pone.0170302.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Janssen</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Soiland</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Skaland</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Gudlaugson</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Kjellevold</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Nysted</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged &lt;55 years</article-title>. <source>Cellular oncology: the official journal of the International Society for Cellular Oncology</source>. <year>2007</year>;<volume>29</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>35</lpage>. Epub 2007/04/13.</mixed-citation></ref>
<ref id="pone.0170302.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Shan</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Yao</surname> <given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer</article-title>. <source>Mol Med Rep</source>. <year>2015</year>;<volume>12</volume>(<issue>4</issue>):<fpage>5246</fpage>–<lpage>54</lpage>. Epub 2015/07/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/mmr.2015.4037" xlink:type="simple">10.3892/mmr.2015.4037</ext-link></comment> <object-id pub-id-type="pmid">26151180</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beca</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Andre</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Martins</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Bilhim</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Martins</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Schmitt</surname> <given-names>F</given-names></name>. <article-title>p-mTOR expression is associated with better prognosis in luminal breast carcinoma</article-title>. <source>Journal of clinical pathology</source>. <year>2014</year>;<volume>67</volume>(<issue>11</issue>):<fpage>961</fpage>–<lpage>7</lpage>. Epub 2014/07/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jclinpath-2014-202320" xlink:type="simple">10.1136/jclinpath-2014-202320</ext-link></comment> <object-id pub-id-type="pmid">25053543</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lazaridis</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Lambaki</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Karayannopoulou</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Eleftheraki</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>Papaspirou</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Bobos</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer</article-title>. <source>Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]</source>. <year>2014</year>;<volume>190</volume>(<issue>7</issue>):<fpage>636</fpage>–<lpage>8</lpage>, <fpage>40</fpage>–<lpage>5</lpage>. Epub 2014/03/25.</mixed-citation></ref>
<ref id="pone.0170302.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bose</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chandran</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mirocha</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Bose</surname> <given-names>N</given-names></name>. <article-title>The Akt pathway in human breast cancer: a tissue-array-based analysis</article-title>. <source>Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc</source>. <year>2006</year>;<volume>19</volume>(<issue>2</issue>):<fpage>238</fpage>–<lpage>45</lpage>. Epub 2005/12/13.</mixed-citation></ref>
<ref id="pone.0170302.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bakarakos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Theohari</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Nomikos</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mylona</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Papadimitriou</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Dimopoulos</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas</article-title>. <source>Histopathology</source>. <year>2010</year>;<volume>56</volume>(<issue>7</issue>):<fpage>876</fpage>–<lpage>82</lpage>. Epub 2010/07/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2559.2010.03570.x" xlink:type="simple">10.1111/j.1365-2559.2010.03570.x</ext-link></comment> <object-id pub-id-type="pmid">20636791</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ueng</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Hsueh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>YC</given-names></name>, <name name-style="western"><surname>Chien</surname> <given-names>HP</given-names></name>, <etal>et al</etal>. <article-title>Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas</article-title>. <source>International journal of clinical and experimental pathology</source>. <year>2012</year>;<volume>5</volume>(<issue>8</issue>):<fpage>806</fpage>–<lpage>13</lpage>. Epub 2012/10/17. <object-id pub-id-type="pmid">23071863</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>An</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jeong</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Woo</surname> <given-names>SU</given-names></name>, <name name-style="western"><surname>Seo</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>A</given-names></name>. <article-title>Phosphorylated Akt and Phosphorylated mTOR Expression in Breast Invasive Carcinomas: Analysis of 530 Cases</article-title>. <source>J Breast Cancer</source>. <year>2010</year>;<volume>13</volume>(<issue>4</issue>):<fpage>337</fpage>–<lpage>48</lpage>.</mixed-citation></ref>
<ref id="pone.0170302.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beelen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Opdam</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Severson</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Koornstra</surname> <given-names>RH</given-names></name>, <name name-style="western"><surname>Vincent</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Wesseling</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment</article-title>. <source>Breast cancer research: BCR</source>. <year>2014</year>;<volume>16</volume>(<issue>1</issue>):<fpage>R6</fpage>. Epub 2014/01/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/bcr3598" xlink:type="simple">10.1186/bcr3598</ext-link></comment> <object-id pub-id-type="pmid">24447434</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cota</surname> <given-names>GF</given-names></name>, <name name-style="western"><surname>de Sousa</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Fereguetti</surname> <given-names>TO</given-names></name>, <name name-style="western"><surname>Rabello</surname> <given-names>A</given-names></name>. <article-title>Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison</article-title>. <source>PLoS neglected tropical diseases</source>. <year>2013</year>;<volume>7</volume>(<issue>5</issue>):<fpage>e2195</fpage>. Epub 2013/05/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002195" xlink:type="simple">10.1371/journal.pntd.0002195</ext-link></comment> <object-id pub-id-type="pmid">23658850</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guertin</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Sabatini</surname> <given-names>DM</given-names></name>. <article-title>Defining the role of mTOR in cancer</article-title>. <source>Cancer cell</source>. <year>2007</year>;<volume>12</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>22</lpage>. Epub 2007/07/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccr.2007.05.008" xlink:type="simple">10.1016/j.ccr.2007.05.008</ext-link></comment> <object-id pub-id-type="pmid">17613433</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dillon</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Muller</surname> <given-names>WJ</given-names></name>. <article-title>The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer</article-title>. <source>Oncogene</source>. <year>2007</year>;<volume>26</volume>(<issue>9</issue>):<fpage>1338</fpage>–<lpage>45</lpage>. Epub 2007/02/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.onc.1210202" xlink:type="simple">10.1038/sj.onc.1210202</ext-link></comment> <object-id pub-id-type="pmid">17322919</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heinonen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Nieminen</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Saarela</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kallioniemi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Klefstrom</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hautaniemi</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer</article-title>. <source>BMC genomics</source>. <year>2008</year>;<volume>9</volume>:<fpage>348</fpage>. Epub 2008/07/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-9-348" xlink:type="simple">10.1186/1471-2164-9-348</ext-link></comment> <object-id pub-id-type="pmid">18652687</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Annovazzi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Mellai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Caldera</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Valente</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Tessitore</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Schiffer</surname> <given-names>D</given-names></name>. <article-title>mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma</article-title>. <source>Anticancer research</source>. <year>2009</year>;<volume>29</volume>(<issue>8</issue>):<fpage>3087</fpage>–<lpage>94</lpage>. Epub 2009/08/08. <object-id pub-id-type="pmid">19661320</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cai</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>Q</given-names></name>. [<article-title>Relationship between expression of mTOR and prognosis of early stage non-small cell lung cancer</article-title>]. <source>Zhonghua zhong liu za zhi [Chinese journal of oncology]</source>. <year>2014</year>;<volume>36</volume>(<issue>2</issue>):<fpage>120</fpage>–<lpage>2</lpage>. Epub 2014/05/07.</mixed-citation></ref>
<ref id="pone.0170302.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leal</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Garcia</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sandoval</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Letelier</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Brebi</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ili</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma</article-title>. <source>Archives of pathology &amp; laboratory medicine</source>. <year>2013</year>;<volume>137</volume>(<issue>4</issue>):<fpage>552</fpage>–<lpage>7</lpage>. Epub 2013/04/03.</mixed-citation></ref>
<ref id="pone.0170302.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anagnostou</surname> <given-names>VK</given-names></name>, <name name-style="western"><surname>Bepler</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Syrigos</surname> <given-names>KN</given-names></name>, <name name-style="western"><surname>Tanoue</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Gettinger</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Homer</surname> <given-names>RJ</given-names></name>, <etal>et al</etal>. <article-title>High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>(<issue>12</issue>):<fpage>4157</fpage>–<lpage>64</lpage>. Epub 2009/06/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-09-0099" xlink:type="simple">10.1158/1078-0432.CCR-09-0099</ext-link></comment> <object-id pub-id-type="pmid">19509151</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Qiu</surname> <given-names>ZX</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>WM</given-names></name>. <article-title>The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer: a systematic review and meta-analysis</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>2</issue>):<fpage>e0116771</fpage>. Epub 2015/02/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0116771" xlink:type="simple">10.1371/journal.pone.0116771</ext-link></comment> <object-id pub-id-type="pmid">25680114</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paplomata</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>O'Regan</surname> <given-names>R</given-names></name>. <article-title>The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers</article-title>. <source>Therapeutic advances in medical oncology</source>. <year>2014</year>;<volume>6</volume>(<issue>4</issue>):<fpage>154</fpage>–<lpage>66</lpage>. Epub 2014/07/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/1758834014530023" xlink:type="simple">10.1177/1758834014530023</ext-link></comment> <object-id pub-id-type="pmid">25057302</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baselga</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Campone</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Piccart</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Burris</surname> <given-names>HA</given-names> <suffix>3rd</suffix></name>, <name name-style="western"><surname>Rugo</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Sahmoud</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>(<issue>6</issue>):<fpage>520</fpage>–<lpage>9</lpage>. Epub 2011/12/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1109653" xlink:type="simple">10.1056/NEJMoa1109653</ext-link></comment> <object-id pub-id-type="pmid">22149876</object-id></mixed-citation></ref>
<ref id="pone.0170302.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ito</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Masuda</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Iwata</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Mukai</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Horiguchi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tokuda</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. [<article-title>Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer—Japanese subgroup analysis of BOLERO -2</article-title>]. <source>Gan to kagaku ryoho Cancer &amp; chemotherapy</source>. <year>2015</year>;<volume>42</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>75</lpage>. Epub 2015/01/19.</mixed-citation></ref>
<ref id="pone.0170302.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Andre</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>O'Regan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ozguroglu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Toi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Jerusalem</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial</article-title>. <source>The Lancet Oncology</source>. <year>2014</year>;<volume>15</volume>(<issue>6</issue>):<fpage>580</fpage>–<lpage>91</lpage>. Epub 2014/04/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(14)70138-X" xlink:type="simple">10.1016/S1470-2045(14)70138-X</ext-link></comment> <object-id pub-id-type="pmid">24742739</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>